Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment response monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test, tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions. Learn more at: natera.com/oncology